Better than Wegovy from Novo Nordisk

New favorite in the treatment race

In addition to the weight loss itself, the researchers behind the study emphasize that Zepbound surpassed Wegovy on all evaluation parameters. It strengthens Americans’ position in the lucrative market for weight loss medicine, where Novo Nordisk has until recently been the dominant player.

« This data confirms that Zepbound is a leading treatment option for people with obesity and gives health professionals important insights into making well -informed treatment decisions as part of a holistic obesity treatment plan, » says Leonard Glass, senior vice president of Eli Lilly’s global medical department.

Stock Exchange and Billion Market

The clinical duel between Zepbound and Wegovy is not only a professional gloom, but also an economic nerve war.

Since the New Year, Novo Nordisk’s share price has dive by about 30 percent, while Eli Lilly – despite the positive results – has seen a fall of just over 5 percent. It clearly shows how sensitive the market is to changes and new knowledge in the struggle to treat obesity globally.

Both companies have invested massively in developing and marketing their medicines – and with the latest figures in mind, it is clear that no one intends to let go of the billion market without a fight.